Pulmonary arterial hypertension (PAH) treatment options have become diverse with the availability of supportive care, medications, and self-care

 

Pulmonary arterial hypertension or pulmonary arterial hypotension is a medical condition that can potentially lead to or be a result of heart disease. Researchers in the field of cardiologists, hypertension experts, and nurse practitioners have been investigating the relationship between diet, gender, and symptoms of pulmonary arterial hypertension (PAH). For years, researchers have been trying to determine if obesity or being overweight could be a cause or result of hypertension.

The causes of pulmonary arterial hypertension (PAH) include many different factors such as smoking, drug use, obesity, history of heart disease, or genetic predisposition. Researchers believe that the increased risk is caused by the increased use of illegal drugs. Illegal drugs such as marijuana and cocaine have been shown to cause an increase in blood pressure that is associated with pulmonary hypertension. Other possible causes include obesity, family history of high blood pressure (HBD), living in a polluted area, and living in an area that is close to air pollution.

The symptoms of pulmonary arterial hypertension include persistent coughing with a nagging cough. The patient may also experience shortness of breath when trying to breathe. This shortness of breath may lead to wheezing and chest pain. Although some of these symptoms may seem like the flu, it is important to note that these symptoms are not always a result of a cold; however, it can be a symptom of the chronic obstructive pulmonary disease (COPD) or an acute attack of the acute respiratory syndrome (Araucana Disease) that can be fatal. The walls of the lungs are made up of several layers of muscle and tissues called the myocardium and the psoas. The contractions of these muscles help carry blood away from the heart to various parts of the body. Recently, in December 2020, Acceleron Pharma Inc., a biopharmaceutical company, received the European Commission (EC) orphan designation for its sotatercept indicated for the treatment of patients with pulmonary arterial hypertension (PAH).